Cofoe Medical Technology Co., Ltd.
可孚醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1187)

PROPOSED APPOINTMENT OF OVERSEAS AUDITOR FOR 2026

This announcement is made by Cofoe Medical Technology Co., Ltd. (the "**Company**") pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, at the 8th meeting of the third session of the Board held on August 28, 2026, upon recommendation by the audit committee of the Board (the "**Audit Committee**"), the Board resolved to propose to appoint Ernst & Young ("**EY Hong Kong**") as the overseas auditor of the Company for the year ending December 31, 2026 with effect from the conclusion of the 2026 third extraordinary general meeting of the Company (the "**EGM**") until the conclusion of the next annual general meeting of the Company, subject to the approval by the shareholders of the Company (the "**Shareholders**") at the EGM.

FACTORS CONSIDERED ON THE APPOINTMENT OF OVERSEAS AUDITOR FOR 2026

The Audit Committee has considered section 2, particularly paragraph 2.2.4 of The Guidelines for Effective Audit Committees – Selection, Appointment and Reappointment of Auditor issued by the Accounting and Financial Reporting Council ("**AFRC**") in December, 2021 as well as the Guidance Notes on Change of Auditor published by the AFRC in September 2023, and is satisfied that EY Hong Kong is independent, competent and capable to perform high quality audits upon the consideration as set out in the Guide, and is satisfied that EY Hong Kong has sufficient and appropriate manpower, expertise, time and resources to perform high quality audits of the Company.

(a) Governance and leadership

EY Hong Kong is a partnership firm established under the laws of Hong Kong, the PRC and is wholly owned by its partners. It renders professional services, including audit, tax and advisory, to a substantial number of Hong Kong listed companies, encompassing financial institutions such as banks, insurance companies and securities firms. Since its establishment, EY Hong Kong has been a member firm of the EY global network and, like Ernst & Young Hua Ming LLP, constitutes an independent legal entity.

With effect from October 1, 2019, EY Hong Kong has been registered as a public interest entity auditor under the Accounting and Financial Reporting Council Ordinance of Hong Kong. In addition, EY Hong Kong has obtained a permit from the Ministry of Finance of the People's Republic of China to temporarily conduct audit services in the Chinese Mainland, and is registered with the U.S. Public Company Accounting Oversight Board (US PCAOB) and the Japanese Financial Services Authority to carry out the relevant audit engagements. EY Hong Kong purchases professional indemnity insurance on an annual basis in compliance with the requirements of the relevant laws and regulations.

(b) Compliance with relevant ethical requirements

The Audit Committee has obtained EY Hong Kong's policies and procedures for ensuring compliance with relevant ethical requirements, including integrity, objectivity and independence.

Since 2020, the Accounting and Financial Reporting Council of Hong Kong has conducted annual inspections on EY Hong Kong in its capacity as a public interest entity auditor. Prior to that, the Hong Kong Institute of Certified Public Accountants carried out similar independent inspections on EY Hong Kong on an annual basis. The practice quality inspections conducted over the past three years have not identified any matters that have a material impact on the audit engagements of EY Hong Kong. EY Hong Kong has confirmed that there are no conflicts of interest that would affect its acceptance of the audit engagement for the year ending December 31, 2026 or its adherence to the Code of Ethics for Professional Accountants issued by the Hong Kong Institute of Certified Public Accountants. The Audit Committee of the Board is of the view that EY Hong Kong possesses the requisite professional qualifications, professional competence, investor protection capabilities, independence and a sound record of integrity.

(c) Industry knowledge and technical competence

The Audit Committee has obtained profile, qualifications of EY Hong Kong's audit team and EY Hong Kong's other relevant audit experience. EY Hong Kong will dedicate a sufficient audit engagement team with experienced professionals, (including partners and managers) to carry out the audit work of the Group. The engagement team is led by a partner with over 18 years of experience in auditing listed companies in different industries. The Audit Committee confirmed that EY Hong Kong has sufficient qualified staff to provide high-quality audit services.

(d) Engagement performance

Based on the audit services rendered by EY Hong Kong as the Company's IPO auditor, EY Hong Kong is able to provide customized services tailored to the Company's audit needs. The Audit Committee is of the view that EY Hong Kong will be able to continue to provide audit services at a level comparable to or better than that delivered during the IPO. In light of the foregoing, the Audit Committee believes that EY Hong Kong has sufficient and appropriate resources, expertise and time to perform high-quality audit work.

(e) Communication and interaction with the Audit Committee

In view of the Audit Committee's past experience of collaborating with the Company's domestic auditor, Ernst & Young Hua Ming LLP (a member firm of the same audit network as EY Hong Kong), as well as with EY Hong Kong itself, the Audit Committee is able to leverage its existing understanding of EY's internal policies and communication practices and apply such understanding to its future collaboration with EY Hong Kong.

(f) Monitoring process

To the best knowledge of the Audit Committee, it is not aware of any acts or activities of EY Hong Kong that may threaten its integrity, objectivity and independence in conducting the audit, or adversely affect its audit quality.

Based on the above, the Audit Committee has assessed EY Hong Kong and considered it to be independent, eligible and suitable to act as the overseas auditor of the Company, and has recommended to the Board the appointment of EY Hong Kong as the overseas auditor of the Company. The Board and the Audit Committee are of the view that the proposed appointment of EY Hong Kong as the overseas auditor of the Company will enhance the cost-effectiveness of the Company's annual audit while maintaining audit quality, and is therefore in the interests of the Company and the Shareholders as a whole.

The overseas auditing fees for 2026 are estimated to be RMB1.4 million to RMB1.8 million, which was determined after due consideration and arm's length negotiations between the Company and EY Hong Kong, taking into account a number of factors, including the Company's business scale, industry and the complexity of its accounting practices, as well as the level of audit resources required and the estimated workload. The estimated audit fee also assumes that there will be no material change in the Company's operations, accounting policies, or regulatory environment during the financial year, and that the Company will provide timely and adequate assistance and information as required for the audit. The Board proposes to the EGM of the Company to authorize the management of the Company to execute relevant agreement(s) with EY Hong Kong.

GENERAL

A circular containing, among other things, further details regarding the proposed appointment of overseas auditor, together with the notice convening the EGM, will be despatched to the Shareholders in due course.

By Order of the Board
Cofoe Medical Technology Co., Ltd.
ZHANG Min
Executive Director and Chairman of the Board

Hong Kong, August 28, 2026

As at the date of this announcement, the Board comprises (i) Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao and Mr. HE Bangjie as executive Directors; and (ii) Mr. NING Huabo, Ms. SHEN Nan and Mr. ZHOU Rong as independent non-executive Directors.